Healthcare >> CEO Interviews >> January 15, 2001
MAX N. WALLACE, President and CEO, Cogent Neuroscience, Inc. has an
extensive history in biotechnology, having co-founded Sphinx
Pharmaceuticals (cellular signal transduction), Trimeris (viral fusion
inhibition) and SARCO (small molecule combinatorial chemistry). He
served as President and as a member of the Board of Directors of both
Trimeris and SARCO. Sphinx had a successful public offering and was
subsequently acquired by Eli Lilly & Co. Trimeris had successful initial
and secondary public offerings and, with partner Hoffman LaRoche, is
moving its first two anti-HIV drugs through clinical trials. SARCO was
acquired by PPD/Pharmaco. In addition, Mr. Wallace was a founding
management director of Duke Management Company, Duke University's asset
management company. He received his BA from Duke University and his JD
from the University of Florida. Profile
including company history, products and services?
Mr. Wallace: Cogent Neuroscience is a functional neurogenomics company.
We
